Nautilus Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nautilus Biotechnology şirketinin toplam hissedar öz sermayesi $223.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $259.7M ve $36.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$140.61m
Eşitlik	US$223.43m
Toplam yükümlülükler	US$36.27m
Toplam varlıklar	US$259.70m

Son finansal sağlık güncellemeleri

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

Jul 27

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 16

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

Oct 22

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

May 25

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 17

Recent updates

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

Jul 27

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 16

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

Oct 22

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

May 25

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NAUT 'nin kısa vadeli varlıkları ( $144.2M ) kısa vadeli yükümlülüklerini ( $8.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: NAUT şirketinin kısa vadeli varlıkları ( $144.2M ) uzun vadeli yükümlülüklerini ( $27.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NAUT borçsuzdur.

Borcun Azaltılması: NAUT son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NAUT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NAUT serbest nakit akışı her yıl % 25.8 1.7 yıl yetecek nakit akışına sahip olacaktır.

Nautilus Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Recent updates

Price target decreased by 14% to US$3.56

Nautilus Biotechnology, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Senior Vice President of Operations notifies of intention to sell stock

Nautilus Biotechnology, Inc. Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

Nautilus Biotechnology, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024

Nautilus Biotechnology, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Co-Founder recently bought US$99k worth of stock

Consensus revenue estimates decrease by 96%, EPS upgraded

Price target decreased by 8.9% to US$4.25

Price target decreased by 8.3% to US$4.58

Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Nautilus Biotechnology, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Price target decreased by 12% to US$4.67

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

Nautilus Biotechnology, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Nautilus Biotechnology, Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Nautilus Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to US$5.00

High number of new and inexperienced directors

Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating Committee

Nautilus Biotechnology, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief People Officer recently bought US$61k worth of stock

Insider recently bought US$163k worth of stock

Co-Founder recently bought US$146k worth of stock

Price target decreased to US$5.67

Nautilus Biotechnology Q2 2022 Earnings Preview

Nautilus Biotechnology, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Co-Founder recently bought US$198k worth of stock

Consensus forecasts updated

Price target decreased to US$8.00

High number of new and inexperienced directors

Nautilus Biotechnology, Inc. Appoints Gwen Weld as Chief People Officer

Nautilus Biotechnology, Inc. to Report Q1, 2022 Results on May 03, 2022

Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Board of Directors

Price target decreased to US$9.33

Nautilus Biotechnology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

The Take On Nautilus Biotechnology

Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point

High number of new and inexperienced directors

CFO & Treasurer recently bought US$69k worth of stock

Independent Director recently bought US$530k worth of stock

Nautilus Biotechnology: Tapping The Potential Of The Human Proteome

Independent Director recently bought US$195k worth of stock

Insider recently bought US$135k worth of stock

Nautilus Biotechnology, Inc. announced that it has received $200 million in funding from a group of investors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin